雪榕生物(300511) - 2021 Q3 - 季度财报(更正)

Financial Performance - The company's revenue for Q3 2021 was ¥500,488,155.72, a decrease of 11.84% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥44,687,522.97, representing a decline of 173.06% year-on-year[3]. - The basic earnings per share were -¥0.10, a decline of 171.43% year-on-year[3]. - Net profit for Q3 2021 was a loss of ¥143,764,632.81, compared to a profit of ¥202,162,091.60 in Q3 2020, indicating a significant decline in profitability[24]. - Total operating revenue for Q3 2021 was ¥1,429,298,969.19, a decrease of 8.56% compared to ¥1,563,472,564.20 in Q3 2020[23]. - Total operating costs increased to ¥1,595,828,968.08, up 15.5% from ¥1,382,054,183.68 in the previous year[23]. - Total comprehensive income for the period was -155,792,313.28 CNY, compared to 195,597,027.22 CNY in the previous period[25]. - Basic and diluted earnings per share were both -0.27 CNY, down from 0.50 CNY and 0.48 CNY respectively in the previous period[25]. Cash Flow and Assets - The net cash flow from operating activities was ¥70,975,793.40, down 80.38% from the previous year[3]. - Cash flow from operating activities generated a net amount of 70,975,793.40 CNY, a significant decrease of 80.4% from 361,815,630.31 CNY in the previous period[28]. - Cash inflow from operating activities totaled 1,476,896,148.38 CNY, down 7.7% from 1,600,004,130.22 CNY in the previous period[28]. - Cash outflow from operating activities was 1,405,920,354.98 CNY, an increase of 13.5% compared to 1,238,188,499.91 CNY in the previous period[28]. - The cash and cash equivalents decreased to ¥312,370,296.71 from ¥759,891,920.58, a decline of 58.9%[20]. - The ending balance of cash and cash equivalents was 310,782,975.99 CNY, down 59.8% from 772,823,507.02 CNY in the previous period[29]. - Current assets totaled ¥910,065,869.52, down 26% from ¥1,228,373,292.27 at the end of 2020[20]. - The company's total assets decreased to ¥4,431,397,663.39 from ¥4,547,783,435.53 at the end of 2020, reflecting a reduction of approximately 2.6%[21]. - Total liabilities rose to ¥2,593,819,338.00, an increase of 2.1% from ¥2,541,797,703.73[21]. - Total liabilities amounted to CNY 2,541,797,703.73, with a slight increase of CNY 20,885,261.24 compared to the previous period[33]. - Current liabilities totaled CNY 1,385,109,958.90, reflecting a decrease of CNY 2,164,248.63 from the previous period[33]. - Non-current liabilities reached CNY 1,156,687,744.83, showing an increase of CNY 18,721,012.61 compared to the last report[33]. Shareholder Information - The equity attributable to shareholders decreased by 8.66% to ¥1,842,497,440.19 compared to the end of the previous year[4]. - The company reported a total of 33,271,375 shares held by the largest shareholder, Yang Yongping, representing a significant portion of the total shares[17]. - The company has a total of 126,178,519 restricted shares at the beginning of the period, with 50,000 shares released during the period[17]. - The company completed the repurchase and cancellation of certain restricted shares on July 29, 2021, without adjusting the conversion price of the convertible bonds[15]. - The company received approval from the China Securities Regulatory Commission for a stock issuance to specific investors on March 24, 2021[15]. - The company is actively pursuing market expansion and strategic initiatives as indicated by its stock issuance plans[14]. - The company has engaged in financing and securities lending activities with its top shareholders, although no specific details were provided[13]. - The company has not reported any related party transactions or concerted actions among its major shareholders[17]. Investment and Expenses - The company reported a significant increase in construction in progress, rising by 88.53% to ¥230,113,403.60 due to new project investments[8]. - The company experienced a 73.61% increase in cash outflow from investing activities, totaling -¥524,884,769.11, primarily due to project construction investments[9]. - The company reported a significant increase in research and development expenses to ¥12,437,740.95, up 29.4% from ¥9,584,250.06 in the previous year[24]. - The company reported a significant increase in payments to employees, totaling 363,377,706.94 CNY, up 16.5% from 311,928,178.12 CNY in the previous period[28]. - The company reported CNY 250,318,751.65 in other payables, which includes various liabilities[33]. - The capital reserve stands at CNY 484,218,723.66, unchanged from the previous period[34].